Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment

Sponsor
University Hospital Muenster (Other)
Overall Status
Completed
CT.gov ID
NCT00824083
Collaborator
German Federal Ministry of Education and Research (Other)
950
2
72
475
6.6

Study Details

Study Description

Brief Summary

The purpose of the study is to assess the functional outcome, quality of life and late sequelae in a representative sample of 600 long-term survivors of Ewing sarcoma and to build a unique clinical and functional data pool of the underlying cohort of 3000 Ewing sarcoma patients with a follow-up of 3 decades.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Trial objective: As survival rates of bone sarcoma patients have been raised owing to improved treatment strategies the focus of investigations is now on the medical, social, and economic sequelae of intensive multimodal treatment. This study aims to assess the functional outcome, quality of life and late sequelae in a representative sample of long-term survivors of Ewing sarcoma. The data recorded combined with standardized treatment data covering a 30-year period will produce a data pool that is unique for its magnitude and will be used for the development of guidelines for further improvements of future bone sarcoma treatment.

    Working plan: The working plan provides for the assessment of functional outcome and quality of life by means of validated tools (TESS, SF36, PEDQOL) and objectively measuring daily activity patterns by using the Step Activity Monitor (SAM) in 600 long-term Ewing sarcoma survivors and a control group of 300 matched healthy subjects. Information on sarcoma treatment and follow-up is obtained by re-structuring and complementing the database of the relevant patient cohort (n=3000) from four consecutive nationwide and international clinical trials between 1980 and 2008. Procedures of local treatment will be evaluated regarding functional outcome, quality of life, and survival probability and prognostic factors predicting long-term outcome will be identified.

    Exploitation of results: The results will be presented at scientific meetings and will be published in international journals. Guidelines will be developed regarding improvements in the treatment, rehabilitation, and social integration of bone sarcoma patients to be utilized in guiding patients and in the decision process of medical professionals regarding their treatment. In the long run, the evidence based guidelines on treatment and follow-up are to be transferred into the health system.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    950 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment
    Study Start Date :
    Jul 1, 2009
    Actual Primary Completion Date :
    Jul 1, 2015
    Actual Study Completion Date :
    Jul 1, 2015

    Arms and Interventions

    Arm Intervention/Treatment
    1

    sarcoma survivors

    2

    healthy subjects

    Outcome Measures

    Primary Outcome Measures

    1. physical activity (SAM: step-activity-monitor) [3-30years after primary diagnosis of Ewing sarcoma]

    Secondary Outcome Measures

    1. health-related quality of life (SF36, PEDQOL) [3-30years after primary diagnosis of Ewing sarcoma]

    2. functional status (TESS) [3-30years after primary diagnosis of Ewing sarcoma]

    3. psychological status (HADS, BIS-BAS) [3-30years after primary diagnosis of Ewing sarcoma]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    6 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • CESS81/CESS86/EICESS92/EURO-E.W.I.N.G.99 trials participants of the German Society of Pediatric Hematology and Oncology (GPOH)
    Exclusion Criteria:
    • no complete remission (CR)

    • any kind of paralysis

    • <3y after diagnosis

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster North Rhine Westphalia Germany 48129
    2 Motion Analysis Lab, Orthopedic Department, University Hospital Münster North Rhine Westphalia Germany 48129

    Sponsors and Collaborators

    • University Hospital Muenster
    • German Federal Ministry of Education and Research

    Investigators

    • Principal Investigator: Andreas Ranft, Dr., University Hospital Muenster
    • Study Chair: Heribert Jürgens, Prof., University Hospital Muenster

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University Hospital Muenster
    ClinicalTrials.gov Identifier:
    NCT00824083
    Other Study ID Numbers:
    • 01ER0807
    First Posted:
    Jan 16, 2009
    Last Update Posted:
    Apr 28, 2016
    Last Verified:
    Apr 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by University Hospital Muenster
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 28, 2016